

Date: May 9, 2002

By: Luisa Bigornia
Luisa Bigornia
Attorney for Applicants
Registration No.: 45,974
HYSEQ, INC.
670 Almanor Avenue
Sunnyvale, CA 94085
(408) 524-8100
(408) 524-8145 (Telefacsimile)

IN THE CLAIMS:

Claims 19, 20 and 26 were cancelled.

Claims 24, 25 and 26 have been amended as follows:

24. (Amended) A method of [treatment] treating wounds by increasing coagulation, said method comprising administering to a mammalian subject [in need thereof] having a wound a therapeutic amount of a composition comprising a polypeptide of claim 10 and a pharmaceutically acceptable carrier.

25. (Twice amended) An isolated polypeptide having prothrombinase activity comprising of an amino acid sequence which is at least 99% [identical] identity to the amino acid sequence SEQ ID NO: [4 or] 9.

30. (Amended) An isolated polypeptide, comprising [with prothrombinase activity having at least an amino acid sequence of] SEQ ID NO: 9, wherein [A=Alanine, C=Cysteine, D=Aspartic Acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine] said polypeptide has prothrombinase activity.